Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
WEST LAFAYETTE, Ind., May 02, 2018 -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Wednesday, May 9th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
Website Information
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
